Methylene Blue Combined with Ropivacaine for Intercostal Nerve Block After Autologous Costal Cartilage Removal in Juvenile Patients

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Autologous costal cartilage is commonly used as a graft material in plastic surgery.

However, after autologous costal cartilage removal, the pain at the surgical site is particularly strong.

Why It Was Studied

This journal requires that authors assign a level of evidence to each article.

For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Who Took Part

The study group was 90 patients.

PubMed indexes the participants as children and teenagers.

Two trained researchers observed and recorded the pain status of the children at 6 hours (T1), 24 hours (T2), 48 hours (T3), and 72 hours (T4) after surgery, respectively.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

Numerical rating pain scale (NRS) was used for scoring.

And adverse reactions such as nausea, vomiting, and skin itching were recorded.

What Was Measured

This journal requires that authors assign a level of evidence to each article.

The subject headings attached to it are Ropivacaine, Methylene Blue, Costal Cartilage, Intercostal Nerves and Pain.

Author keywords: Intercostal nerve block.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 90 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Aesthetic plastic surgery), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.